Skip to main content
OpenTrials
Completed

NCT Number: NCT01477931

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with MDD with atypical features.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depressive Disorder, Major Depressive Disorder Mental Disorders Mood Disorders

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Korea University Ansan Hospital, Ansan, Gyeonggi-do, South Korea

Loading trial locations.

About this study

Whether bupropion hydrochloride extended release (Wellbutrin XL®) improved atypical depressive symptoms has not been investigated. The investigators assumed that bupropion hydrochloride extended release (Wellbutrin XL®) will be effective and tolerable in the treatment of atypical depression in MDD patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age over 20 years
  • DSM-IV episode of MDD non-psychotic with atypical features characterized by mood reactivity and 2 or more symptoms of vegetative reversal (including overeating, oversleeping, severe fatigue or leaden paralysis, and a history of rejection sensitivity)
  • More than 19 score on the 29-item HAM-D
  • Ability to give informed consent

Exclusion criteria

  • Bipolar depression
  • Any Axis I psychotic disorder
  • A history of suicide attempt, self-injurious action (excluding action with no intention of suicide) or overdosage (excluding apparently accidental overdosage)
  • Patients with more than 3-point score of suicide (HAM-D-29 Item 18) or patients whose C-SSRS assessment suggests that they are or have been at significant risk for harming themselves or have actually harmed themselves, or who, in the opinion of the investigator (sub-investigator), are at significant risk for harming self or others
  • A history of substance abuse in the previous 12 months
  • A history of hypersensitivity to bupropion or any other components of the preparations used in the study (Wellbutrin SR 150mg and Wellbutrin XL 300 mg tablets)
  • Serious or unstable medical disorders
  • Starting or terminating psychotherapy during the previous 12 weeks,
  • ECT treatment in the previous 3 months
  • Subject has a life time diagnosis of anorexia nervosa or bulimia within the past 12 month
  • Subject has a current or history of seizure disorder or brain injury (traumatic or disease-related) or any condition which predisposes to seizure- subject treated with other medications or treatment regimens that lower seizure threshold- subject undergoing abrupt discontinuation of alcohol or sedatives
  • Subjects that previously failed adequate courses of pharmacotherapy from two different classes of antidepressants or previous adequate course(s) of bupropion
  • Pregnancy or planning pregnancy - when a patient is in active reproductive age, he or she has to agree to use relevant contraception during the study
  • Patients on monoamine oxidase inhibitors (MAOIs)
  • Patients being treated with any other preparations containing bupropion as the incidence of seizures is dose dependent

Treatment and study plan

Bupropion extended release

Drug

300mg once a daily, PO, 8weeks

Other names: Wellbutrin XL

Primary outcomes

  1. HAM-D-29 scores(Hamilton Depression Rating Scale 29)

    Time frame: 8 weeks

    Changes in HAM-D-29 scores from baseline to the end of treatment.

Secondary outcomes

  1. 8-atypical items on the HAM-D-29

    Time frame: 8 weeks

    8-atypical items on the HAM-D-29 from baseline to end of treatment.

  2. Tolerability

    Time frame: 8 weeks

    Tolerability evaluations will be determined by TEAEs(treatment-emergent adverse events) and vital signs recording.

  3. CGI-I score(Clinical Global Impression Improvement score)

    Time frame: 8 weeks

    CGI-I score of 1 or 2 (proportion of the patients achieving this point at the end of treatment) or changes in total scores on CGI-S

  4. SDS(Zung Self-Rating Depression Scale)

    Time frame: 8 weeks

    Change of SDS from baseline to end of treatment.

  5. C-SSRS(The Columbia-Suicide Severity Rating Scale, changes in behaviours and ideation)

    Time frame: 8 weeks

    Change of C-SSRS from baseline to end of treatment.

  6. ESQ(Epworth Sleepiness Questionnaire)

    Time frame: 8 weeks

    Change of ESQ from baseline to end of treatment.

  7. Response

    Time frame: 8 weeks

    Response will be defined as 50% or greater reduction in HAM-D-29 scores from baseline to end of treatment.

  8. Remission

    Time frame: 8 weeks

    Remission will be defined as a HAM-D-29 score of ≤ 7.

Sponsors and collaborators

Lead sponsor

Chi-Un Pae

Other

Collaborators

  • GlaxoSmithKline

Registry information

Official study title

An Open-Label, 8-week Trial of Bupropion Hydrochloride Extended Release (Wellbutrin XL®) In Patients With Major Depressive Disorder (MDD) With Atypical Features.

Acronym: WellbutrinXL

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Nov 23, 2011
Registry last updated
Nov 23, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.